Rexahn Pharmaceuticals, Inc. (RNN) Receives Outperform Rating from FBR & Co
Separately, Zacks Investment Research upgraded Rexahn Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 21st.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 0.3756% during mid-day trading on Wednesday, hitting $0.2122. 216,065 shares of the company traded hands. The firm’s market cap is $45.26 million. Rexahn Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $0.52. The firm has a 50-day moving average price of $0.24 and a 200 day moving average price of $0.27.
Rexahn Pharmaceuticals (NYSE:RNN) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Equities research analysts anticipate that Rexahn Pharmaceuticals will post ($0.07) EPS for the current fiscal year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its position in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.